Related Experiment Video
Updated: Jul 9, 2025

Using the E1A Minigene Tool to Study mRNA Splicing Changes
Published on: April 22, 2021
CDK11 requires a critical activator SAP30BP to regulate pre-mRNA splicing
Changshou Wang1, Lin Xu1, Chen Du2
1Key Laboratory of RNA Science and Engineering, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Abstract:
CDK11 is an emerging druggable target for cancer therapy due to its prevalent roles in phosphorylating critical transcription and splicing factors and in facilitating cell cycle progression in cancer cells. Like other cyclin-dependent kinases, CDK11 requires its cognate cyclin, cyclin L1 or cyclin L2, for activation. However, little is known about how CDK11 activities might be modulated by other regulators. In this study, we show that CDK11 forms a tight complex with cyclins L1/L2 and SAP30BP, the latter of which is a poorly characterized factor. Acute degradation of SAP30BP mirrors that of CDK11 in causing widespread and strong defects in pre-mRNA splicing. Furthermore, we demonstrate that SAP30BP facilitates CDK11 kinase activities in vitro and in vivo, through ensuring the stabilities and the assembly of cyclins L1/L2 with CDK11. Together, these findings uncover SAP30BP as a critical CDK11 activator that regulates global pre-mRNA splicing.
Insights
SAP30BP is identified as a crucial activator for CDK11 (cyclin-dependent kinase 11), a key target in cancer therapy. This interaction is vital for regulating pre-mRNA splicing, impacting cell cycle progression in cancer cells.
Area of Science:
- Molecular Biology
- Cancer Biology
- Biochemistry
Background:
- CDK11 (cyclin-dependent kinase 11) is a promising target for cancer therapy due to its roles in cell cycle progression and phosphorylation of transcription/splicing factors.
- CDK11 activation requires cyclin L1 or L2, but other regulatory mechanisms remain largely unknown.
Purpose of the Study:
- To investigate novel regulators of CDK11 activity.
- To elucidate the role of SAP30BP in CDK11 function and its impact on pre-mRNA splicing.
Main Methods:
- Co-immunoprecipitation to study protein complex formation.
- In vitro kinase assays to assess CDK11 activity.
- In vivo degradation studies to evaluate protein stability and function.
- Analysis of pre-mRNA splicing defects.
Main Results:
- SAP30BP forms a stable complex with CDK11 and cyclins L1/L2.
- SAP30BP degradation leads to defects in pre-mRNA splicing, similar to CDK11 loss.
- SAP30BP enhances CDK11 kinase activity by stabilizing cyclin L1/L2 association with CDK11.
- SAP30BP is essential for maintaining global pre-mRNA splicing.
Conclusions:
- SAP30BP is identified as a critical activator of CDK11.
- SAP30BP plays a vital role in regulating global pre-mRNA splicing through CDK11 modulation.
- These findings highlight SAP30BP as a potential therapeutic target in conjunction with CDK11 for cancer treatment.
Related Concept Videos
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Pre-mRNA Processing: RNA Splicing
Inhibition of Cdk Activity
Anaphase Promoting Complex

